Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010163 | 0.81 | MAOB (0.51) | MAOBLMNACCR5 | |
| SCHEMBL29816877 | 0.81 | MAOB (0.51) | MAOBLMNACCR5 | |
| SCHEMBL12577954 | 0.80 | ALDH1A1 (0.45) | MAOBNR4A2RAB9ASMN1; SMN2LMNA | |
| SCHEMBL16016189 | 0.79 | FFAR1 (0.48) | MAOBNR4A2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6346727 | 0.78 | TSHR (0.50) | MAOBRAB9ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL9812484 | 0.77 | NR4A2 (0.69) | MAOBNR4A2RAB9ANPC1LMNA | |
| SCHEMBL28034244 | 0.77 | SLC6A4 (0.41) | SMN1; SMN2LMNANPSR1SLC6A4HTR6 | |
| SCHEMBL1746557 | 0.77 | FFAR1 (0.67) | — | |
| SCHEMBL14966760 | 0.76 | MAOB (0.49) | MAOBRAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL8102862 | 0.76 | NPC1 (0.56) | MAOBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755722-B1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD (IN) | 2017-05-24 | — | — | EP | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439901-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9018249-B2 | SGLT inhibitors | PANACEA BIOTEC LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065565-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065512-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| EP-2496583-B1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20090318547-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2074130-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1928852-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008034859-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008034859-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007031548-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031548-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065512-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | MAOB 1639/4885NR4A2 455/4885RAB9A 3289/4885 |
| US-20150065565-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | MAOB 1639/4885NR4A2 455/4885RAB9A 3289/4885 |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | UGGT1, B3GAT3, UGCG | MAOB 392/4885NR4A2 1655/4885RAB9A 2035/4885 |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | MAOB 1639/4885NR4A2 455/4885RAB9A 3289/4885 |
| US-20090318547-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, SLC5A2, SLC5A1 | MAOB 409/4885NR4A2 2072/4885RAB9A 4446/4885 |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | MAOB 1900/4885NR4A2 2371/4885RAB9A 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.